Synapse

← Human Gene Therapy Clinical Development

Papers in Human Gene Therapy Clinical Development

Page 2 · newest first

  1. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of AchromatopsiaHuman Gene Therapy Clinical Development · 2016
  2. Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of AchromatopsiaHuman Gene Therapy Clinical Development · 2016
  3. A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIBHuman Gene Therapy Clinical Development · 2015
  4. Preclinical and preliminary clinical evaluation of genetically transduced dermal tissue implants for the sustained secretion of erythropoietin and interferon αHuman Gene Therapy Clinical Development · 2015
  5. A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIBHuman Gene Therapy Clinical Development · 2015
  6. Preclinical and Preliminary Clinical Evaluation of Genetically Transduced Dermal Tissue Implants for the Sustained Secretion of Erythropoietin and Interferon αHuman Gene Therapy Clinical Development · 2015
  7. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing RetinoschisinHuman Gene Therapy Clinical Development · 2015
  8. Investor Outlook: Focus on Upcoming LCA2 Gene Therapy Phase III ResultsHuman Gene Therapy Clinical Development · 2015
  9. Safety and Biodistribution Evaluation of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin, in RS1-Deficient MiceHuman Gene Therapy Clinical Development · 2015
  10. Use of Adeno-Associated Virus to Enrich Cardiomyocytes Derived from Human Stem CellsHuman Gene Therapy Clinical Development · 2015
  11. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical PlanningHuman Gene Therapy Clinical Development · 2015
  12. Safety, Biodistribution, and Efficacy of an Aav-5 Vector Encoding Human Interferon-Beta (Art-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys With Collagen-Induced ArthritisHuman Gene Therapy Clinical Development · 2015
  13. Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced ArthritisHuman Gene Therapy Clinical Development · 2015
  14. A Multicenter, Single-Blind, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of a Cell-Mediated Gene Therapy in Degenerative Knee Arthritis PatientsHuman Gene Therapy Clinical Development · 2015
  15. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman PrimatesHuman Gene Therapy Clinical Development · 2015
  16. Duchenne Muscular Dystrophy Gene Therapy in the Canine ModelHuman Gene Therapy Clinical Development · 2015
  17. Ferret and Pig Models of Cystic Fibrosis: Prospects and Promise for Gene TherapyHuman Gene Therapy Clinical Development · 2015
  18. Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in DogsHuman Gene Therapy Clinical Development · 2015
  19. Dog Models for Blinding Inherited Retinal DystrophiesHuman Gene Therapy Clinical Development · 2015
  20. A Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage DisordersHuman Gene Therapy Clinical Development · 2015
  21. Gene Therapy Studies in a Canine Model of X-Linked Severe Combined ImmunodeficiencyHuman Gene Therapy Clinical Development · 2015
  22. Ferret and Pig Models of Cystic Fibrosis: Prospects and Promise for Gene TherapyHuman Gene Therapy Clinical Development · 2014
  23. HEK293-Based Production Platform for γ-Retroviral (Self-Inactivating) Vectors: Application for Safe and Efficient Transfer of COL7A1 cDNAHuman Gene Therapy Clinical Development · 2014
  24. Herpes Simplex Virus Clearance During Purification of a Recombinant Adeno-Associated Virus Serotype 1 VectorHuman Gene Therapy Clinical Development · 2014
  25. Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in RabbitsHuman Gene Therapy Clinical Development · 2014
  26. Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV- GAA ) Gene Vector in Patients with Pompe DiseaseHuman Gene Therapy Clinical Development · 2014
  27. Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman PrimatesHuman Gene Therapy Clinical Development · 2014
  28. Influence of Mildly Acidic pH Conditions on the Production of Lentiviral and Retroviral VectorsHuman Gene Therapy Clinical Development · 2014
  29. Pulsed Versus Continuous Application of the Prodrug 5-Fluorocytosine to Enhance the Oncolytic Effectiveness of a Measles Vaccine Virus Armed with a Suicide GeneHuman Gene Therapy Clinical Development · 2014
  30. Aerosol Delivery of DNA/Liposomes to the Lung for Cystic Fibrosis Gene TherapyHuman Gene Therapy Clinical Development · 2014
  31. Feasibility and Safety of Systemic rAAV9-h NAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in PrimatesHuman Gene Therapy Clinical Development · 2014
  32. Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman PrimatesHuman Gene Therapy Clinical Development · 2014
  33. Clinical Development of Gene Therapy Needs a Tailored Approach: A Regulatory Perspective from the European UnionHuman Gene Therapy Clinical Development · 2014
  34. Preclinical Safety Assessment of Ad[I/PPT-E1A], a Novel Oncolytic Adenovirus for Prostate CancerHuman Gene Therapy Clinical Development · 2014
  35. Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anticocaine VaccineHuman Gene Therapy Clinical Development · 2014
  36. Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human PrimatesHuman Gene Therapy Clinical Development · 2014
  37. Phase I Study Protocol for Ex Vivo Lentiviral Gene Therapy for the Inherited Skin Disease, Netherton SyndromeHuman Gene Therapy Clinical Development · 2013
  38. Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon-γ Gene TransferHuman Gene Therapy Clinical Development · 2013
  39. Safety Studies on Intravenous Administration of Oncolytic Recombinant Vesicular Stomatitis Virus in Purpose-Bred Beagle DogsHuman Gene Therapy Clinical Development · 2013
  40. Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin DeficiencyHuman Gene Therapy Clinical Development · 2013
  41. Biodistribution of AAV8 Vectors Expressing Human Low-Density Lipoprotein Receptor in a Mouse Model of Homozygous Familial HypercholesterolemiaHuman Gene Therapy Clinical Development · 2013
  42. A Seven-Year Storage Report of Good Manufacturing Practice–Grade Naked Plasmid DNA: Stability, Topology, and In Vitro/In Vivo Functional AnalysisHuman Gene Therapy Clinical Development · 2013
  43. Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck CancerHuman Gene Therapy Clinical Development · 2013
  44. Effectiveness and Preclinical Safety Profile of Doxycycline to Be Used “Off-Label” to Induce Therapeutic Transgene Expression in a Phase I Clinical Trial for GliomaHuman Gene Therapy Clinical Development · 2013
  45. Preclinical Toxicology and Biodistribution Studies of Recombinant Adeno-Associated Virus 1 Human Acid α-GlucosidaseHuman Gene Therapy Clinical Development · 2013
  46. Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man StudyHuman Gene Therapy Clinical Development · 2013
  47. From Bench to Bedside: Preclinical Evaluation of a Self-Inactivating Gammaretroviral Vector for the Gene Therapy of X-linked Chronic Granulomatous DiseaseHuman Gene Therapy Clinical Development · 2013
  48. Lessons Learned from the Clinical Development and Market Authorization of GlyberaHuman Gene Therapy Clinical Development · 2013
  49. The Phenotype of Dysferlin-Deficient Mice Is Not Rescued by Adeno-Associated Virus–Mediated Transfer of Anoctamin 5Human Gene Therapy Clinical Development · 2013
  50. Comparison of Insulators and Promoters for Expression of the Wiskott–Aldrich Syndrome Protein Using Lentiviral VectorsHuman Gene Therapy Clinical Development · 2013